Day: May 19, 2024

Qifu Technology Announces First Quarter 2024 Unaudited Financial Results

Qifu Technology Announces First Quarter 2024 Unaudited Financial Results

SHANGHAI, China, May 19, 2024 (GLOBE NEWSWIRE) — Qifu Technology, Inc. (NASDAQ: QFIN; HKEx: 3660) (“Qifu Technology” or the “Company”), a leading Credit-Tech platform in China, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Business Highlights As of March 31, 2024, our platform has connected 159 financial institutional partners and 241.4 million consumers*1 with potential credit needs, cumulatively, an increase of 12.5% from 214.5 million a year ago. Cumulative users with approved credit lines*2 were 52.3 million as of March 31, 2024, an increase of 13.8% from 46.0 million as of March 31, 2023. Cumulative borrowers with successful drawdown, including repeat borrowers were 31.2 million as of March 31, 2024, an increase of 12.6% from 27.7 million as of March 31, 2023. In...

Continue reading

Music Licensing, Inc. (OTC: SONG)  (OTC: SONGD)  Announces Implementation of 1-for-500,000 Reverse Stock Split and Reduction of Outstanding Common Shares

Music Licensing, Inc. (OTC: SONG) (OTC: SONGD) Announces Implementation of 1-for-500,000 Reverse Stock Split and Reduction of Outstanding Common Shares

 Naples, FL, May 19, 2024 (GLOBE NEWSWIRE) —  Music Licensing, Inc. (OTC: SONGD) today announces a significant milestone in its corporate restructuring, as the company prepares to execute a 1-for-500,000 reverse stock split effective May 20, 2024. This strategic move is aimed at optimizing shareholder value and enhancing the company’s financial position. Following the reverse stock split, Music Licensing, Inc. will have approximately 6,004 Common Shares outstanding, a substantial reduction from its previous count. The temporary change in the company’s stock symbol to (OTC: SONGD) for approximately 20 days reflects this transition period. As part of the reverse stock split, fractional shareholders will be provided with a cash payment in lieu of a round-up of fractional shares., in accordance with the company’s...

Continue reading

Key Energy Services Reports Asset Acquisition

Key Energy Services Reports Asset Acquisition

HOUSTON, May 19, 2024 (GLOBE NEWSWIRE) — Key Energy Services, Inc. (“Key” or the “Company”) today announced the purchase of substantially all the assets of the well servicing division of Endeavor Energy Resources, L.P. (“Endeavor”) in an all-cash transaction effective May 19, 2024. Key will continue support Endeavor’s well servicing needs in the Permian Basin with these assets. Key’s President and Chief Executive Officer, Marshall Dodson, stated, “We are excited about this transaction and the great people and assets we have added to our team. We look forward to continuing our relationship with Endeavor, partnering with them to provide the same safe and exceptional service they are accustomed to.” Dodson continued, “I am very proud of the progress our team at Key has made over the past several years, strengthening our balance sheet...

Continue reading

Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET

Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET

WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, and to host a virtual event at 8:00 a.m. ET. This represents an update to Dyne’s prior guidance for the second half of 2024. The company intends to issue a press release prior to the start of the event.  Phase 1/2 ACHIEVE Trial of DYNE-101 in DM1 ACHIEVE is a Phase 1/2 global clinical trial evaluating DYNE-101 in adult patients with myotonic dystrophy type 1 (DM1) who are 18 to 49 years of age. ACHIEVE, which is designed to be a registrational trial,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.